Abcam, ab317777, Human TNFSF15 ELISA Kit- Intracellular

Size: 1 x 96Tests / 1 x 384Tests / 10 x 96Tests
Human TNFSF15 ELISA Kit- Intracellular is a single-wash 90-min Simplestep used to quantify Human TNFSF15 with a sensitivity of 4.122 pg/ml. The assay uses a simple mix-wash-read protocol with just one incubation and one wash step. - Colorimetric Sandwich ELISA - 450 nm readout : works on any standard plate reader - Different formats for different needs: 10x96 plates for bulk orders and 384-well plate for higher throughput - Design your own immunoassay: we also offer the conjugation-ready antibody pair
Key facts
Detection method:Colorimetric,
Sample types:Cell Lysate, Tissue Extracts,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 4.122 pg/mL,
Range:23.438 - 1500 pg/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)

Product details:
Human TNFSF15 SimpleStep ELISA® kit is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of TNFSF15 protein in Cell Lysate, Tissue extracts. Quantitate Human TNFSF15 with 4.122 pg/ml sensitivity.
SimpleStep ELISA
technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA
plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA
protocol summary in the image section for further details. Our SimpleStep ELISA
technology provides several benefits:
-Single-wash protocol reduces assay time to 90 minutes or less
-High sensitivity, specificity and reproducibility from superior antibodies
-Fully validated in biological samples
-96-wells plate breakable into 12 x 8 wells strips, available in 10-pack (10 x 96-well plates)
-Also available in a fully validated 384-well format.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein TL1A also known as TNF-like ligand 1A is part of the tumor necrosis factor (TNF) superfamily. It is a cytokine with a molecular weight of approximately 23 kDa. Cells such as endothelial cells monocytes and fibroblasts express TL1A. TL1A predominantly acts as ligand for death receptor 3 (DR3) also called TNFRSF25 and is involved in immune response regulation. This protein can be found mainly in tissues involved in immune surveillance like lymph nodes and the gastrointestinal tract.
Biological function summary
TL1A interacts to induce T cell proliferation and cytokine production. It forms a complex with DR3 to activate downstream signaling pathways. These activities enhance adaptive immunity by stimulating T helper cells. Furthermore TL1A influences the production of inflammatory cytokines like interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α). Through its interaction with DR3 TL1A modulates important immune responses.
Pathways
TL1A features in the TNF receptor-mediated signaling and the NF-kB signaling pathway. In these pathways it links to proteins such as RIPK1 and TRAF2. The signaling through DR3 influences cell survival differentiation and apoptosis. These pathways are important in maintaining the balance between immune activation and tolerance. By interacting with various signaling molecules TL1A orchestrates complex immune functions that ensure adequate immune responses and prevent autoimmunity.
Researchers connect TL1A with conditions like inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). These conditions involve chronic inflammation and immune dysregulation where TL1A plays a role. In IBD elevated TL1A levels drive inflammation in the intestines. In RA TL1A potentially interacts with fibroblast-like synoviocytes contributing to joint inflammation and damage. Its relation to DR3 further implicates TL1A in these autoimmune disorders making it a target for therapeutic interventions aiming to mitigate immune-mediated damage.